BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xie ZB, Ma L, Wang XB, Bai T, Ye JZ, Zhong JH, Li LQ. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. Tumour Biol. 2014;35:8451-8459. [PMID: 25038916 DOI: 10.1007/s13277-014-2340-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Solaini L, Cucchetti A, Piccino M, Gardini A, La Barba G, Serenari M, Cescon M, Ercolani G. Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncol 2019;15:439-49. [PMID: 30620230 DOI: 10.2217/fon-2018-0269] [Reference Citation Analysis]
2 Lungren MP, Towbin AJ, Roebuck DJ, Monroe EJ, Gill AE, Thakor A, Towbin RB, Cahill AM, Matthew Hawkins C. Role of interventional radiology in managing pediatric liver tumors : Part 1: Endovascular interventions. Pediatr Radiol. 2018;48:555-564. [PMID: 29362840 DOI: 10.1007/s00247-018-4068-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
3 Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017;17:645. [PMID: 28899349 DOI: 10.1186/s12885-017-3545-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
4 Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
5 Zhang Y, Zhang X, Zhang J, Sun B, Zheng L, Li J, Liu S, Sui G, Yin Z. Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay. Cancer Biol Ther 2016;17:1177-87. [PMID: 27662377 DOI: 10.1080/15384047.2016.1235665] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
6 Qi X, Zhao Y, Li H, Guo X, Han G. Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. Oncotarget 2016;7:34703-51. [PMID: 27167195 DOI: 10.18632/oncotarget.9157] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
7 Xie ZB, Wang XB, Peng YC, Zhu SL, Ma L, Xiang BD, Gong WF, Chen J, You XM, Jiang JH, Li LQ, Zhong JH. Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res. 2015;45:190-200. [PMID: 25388603 DOI: 10.1111/hepr.12450] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
8 Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK, Are C. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg. 2016;263:1112-1125. [PMID: 26813914 DOI: 10.1097/sla.0000000000001556] [Cited by in Crossref: 124] [Cited by in F6Publishing: 86] [Article Influence: 24.8] [Reference Citation Analysis]
9 Xu X, Chen C, Liu Q, Huang X. A Meta-analysis of TAE/TACE Versus Emergency Surgery in the Treatment of Ruptured HCC. Cardiovasc Intervent Radiol 2020;43:1263-76. [PMID: 32440961 DOI: 10.1007/s00270-020-02514-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Narsinh KH, Duncan DP, Newton IG, Minocha J, Rose SC. Liver-directed therapy for hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:203-17. [PMID: 29230556 DOI: 10.1007/s00261-017-1435-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
11 Roth GS, Teyssier Y, Abousalihac M, Seigneurin A, Ghelfi J, Sengel C, Decaens T. Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. World J Gastroenterol 2020; 26(3): 324-334 [PMID: 31988592 DOI: 10.3748/wjg.v26.i3.324] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
12 Huang M, Wang X, Bin H. Effect of Transcatheter Arterial Chemoembolization Combined with Argon-Helium Cryosurgery System on the Changes of NK Cells and T Cell Subsets in Peripheral Blood of Hepatocellular Carcinoma Patients. Cell Biochem Biophys. 2015;73:787-792. [PMID: 27259326 DOI: 10.1007/s12013-015-0699-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
13 Zheng L, Guo CY, Chen CS, Xiao JC, Hu HT, Cheng HT, Zong DW, Jiang L, Li HL. Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study. Oncotarget 2017;8:97613-22. [PMID: 29228637 DOI: 10.18632/oncotarget.18811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhong J, Tan J, Li L, Wu W, Zhao C. Transarterial Embolization With or Without Chemotherapy: What Should Be the Indication for Patients With Hepatocellular Carcinoma? JCO 2017;35:257-8. [DOI: 10.1200/jco.2016.68.4902] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Facciorusso A, Bellanti F, Villani R, Salvatore V, Muscatiello N, Piscaglia F, Vendemiale G, Serviddio G. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials. United European Gastroenterol J. 2017;5:511-518. [PMID: 28588882 DOI: 10.1177/2050640616673516] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
16 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
17 Long D, Yu PC, Huang W, Luo YL, Zhang S. Systematic review of partial hepatic resection to treat hepatic metastases in patients with gastric cancer. Medicine (Baltimore) 2016;95:e5235. [PMID: 27858875 DOI: 10.1097/MD.0000000000005235] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hodavance MS, Vikingstad EM, Griffin AS, Pabon-ramos WM, Berg CL, Suhocki PV, Kim CY. Effectiveness of Transarterial Embolization of Hepatocellular Carcinoma as a Bridge to Transplantation. Journal of Vascular and Interventional Radiology 2016;27:39-45. [DOI: 10.1016/j.jvir.2015.08.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
19 Scaffaro LA, Kruel CD, Stella SF, Gravina GL, Machado Filho G, Borges de Almeida CP, Pinto LC, Alvares-da-Silva MR, Kruel CR. Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres. Biomed Res Int 2015;2015:435120. [PMID: 26413523 DOI: 10.1155/2015/435120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]